Stock listing
OTC:CERO CERo Therapeutics Holdings, Inc. Stock
Follow CERo Therapeutics Holdings, Inc. into a list and get an email when it puts out news.
Share price · OTC:CERO
$0.0037 USD -0.0003 (-7.5%)
Close on Nov 20, 2026
- Day range
- $0.0037 – $0.0043 USDNov 20, 2026
- Volume
- 124,170 sharesNov 20, 2026
- Market cap
- $265,035 USDAt the close on Nov 20, 2026 · price × 71.63M shares outstanding
- 52-week range
- $0.0030 – $0.1350 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $5,041 USDMedian day 299,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:CERO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0037 | -0.0003 | -7.5% | $0.0043 | $0.0043 | $0.0037 | 124,170 | |
| $0.0040 | -0.0001 | -2.4% | $0.0041 | $0.0041 | $0.0040 | 70,020 | |
| $0.0041 | 0.0000 | 0.0% | $0.0040 | $0.0047 | $0.0040 | 82,491 | |
| $0.0041 | 0.0000 | 0.0% | $0.0048 | $0.0049 | $0.0041 | 34,588 | |
| $0.0041 | +0.0001 | +2.5% | $0.0039 | $0.0048 | $0.0037 | 329,551 | |
| $0.0040 | -0.0010 | -20.0% | $0.0040 | $0.0050 | $0.0040 | 179,700 | |
| $0.0050 | +0.0010 | +25.0% | $0.0040 | $0.0050 | $0.0040 | 90,200 | |
| $0.0040 | +0.0010 | +33.3% | $0.0050 | $0.0050 | $0.0040 | 99,300 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0050 | $0.0030 | 123,900 | |
| $0.0030 | -0.0010 | -25.0% | $0.0050 | $0.0050 | $0.0030 | 163,700 | |
| $0.0040 | -0.0010 | -20.0% | $0.0050 | $0.0050 | $0.0040 | 44,400 | |
| $0.0050 | +0.0010 | +25.0% | $0.0040 | $0.0050 | $0.0040 | 605,700 | |
| $0.0040 | 0.0000 | 0.0% | $0.0040 | $0.0040 | $0.0030 | 126,400 | |
| $0.0040 | -0.0010 | -20.0% | $0.0050 | $0.0050 | $0.0030 | 1,306,900 | |
| $0.0050 | 0.0000 | 0.0% | $0.0050 | $0.0050 | $0.0040 | 211,600 | |
| $0.0050 | 0.0000 | 0.0% | $0.0050 | $0.0050 | $0.0050 | 297,300 | |
| $0.0050 | -0.0010 | -16.7% | $0.0060 | $0.0060 | $0.0040 | 1,633,400 | |
| $0.0060 | +0.0010 | +20.0% | $0.0050 | $0.0060 | $0.0050 | 465,800 | |
| $0.0050 | 0.0000 | 0.0% | $0.0060 | $0.0060 | $0.0040 | 103,100 | |
| $0.0050 | 0.0000 | 0.0% | $0.0050 | $0.0060 | $0.0050 | 188,900 | |
| $0.0050 | 0.0000 | 0.0% | $0.0050 | $0.0050 | $0.0040 | 42,500 | |
| $0.0050 | -0.0010 | -16.7% | $0.0050 | $0.0060 | $0.0040 | 654,100 | |
| $0.0060 | 0.0000 | 0.0% | $0.0060 | $0.0060 | $0.0050 | 234,800 | |
| $0.0060 | 0.0000 | 0.0% | $0.0060 | $0.0070 | $0.0050 | 534,700 | |
| $0.0060 | -0.0010 | -14.3% | $0.0070 | $0.0070 | $0.0060 | 38,800 | |
| $0.0070 | 0.0000 | 0.0% | $0.0070 | $0.0070 | $0.0050 | 1,355,800 | |
| $0.0070 | 0.0000 | 0.0% | $0.0080 | $0.0080 | $0.0060 | 1,548,100 | |
| $0.0070 | -0.0020 | -22.2% | $0.0090 | $0.0090 | $0.0070 | 2,056,100 | |
| $0.0090 | 0.0000 | 0.0% | $0.0090 | $0.0090 | $0.0080 | 1,112,600 | |
| $0.0090 | -0.0010 | -10.0% | $0.0090 | $0.0100 | $0.0090 | 1,602,900 | |
| $0.0100 | +0.0010 | +11.1% | $0.0120 | $0.0120 | $0.0090 | 858,000 | |
| $0.0090 | -0.0010 | -10.0% | $0.0110 | $0.0110 | $0.0090 | 571,200 | |
| $0.0100 | -0.0010 | -9.1% | $0.0110 | $0.0110 | $0.0090 | 1,143,700 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 252,600 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 171,300 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0110 | 674,800 | |
| $0.0110 | 0.0000 | 0.0% | $0.0120 | $0.0120 | $0.0110 | 249,200 | |
| $0.0110 | 0.0000 | 0.0% | $0.0110 | $0.0120 | $0.0110 | 396,800 | |
| $0.0110 | -0.0010 | -8.3% | $0.0120 | $0.0120 | $0.0100 | 224,700 | |
| $0.0120 | 0.0000 | 0.0% | $0.0120 | $0.0120 | $0.0110 | 220,300 | |
| $0.0120 | 0.0000 | 0.0% | $0.0120 | $0.0120 | $0.0100 | 422,400 | |
| $0.0120 | +0.0010 | +9.1% | $0.0100 | $0.0130 | $0.0100 | 541,700 | |
| $0.0110 | +0.0010 | +10.0% | $0.0130 | $0.0130 | $0.0100 | 408,700 | |
| $0.0100 | -0.0010 | -9.1% | $0.0090 | $0.0120 | $0.0090 | 153,600 | |
| $0.0110 | -0.0020 | -15.4% | $0.0130 | $0.0130 | $0.0100 | 71,100 | |
| $0.0130 | +0.0010 | +8.3% | $0.0130 | $0.0130 | $0.0100 | 301,900 | |
| $0.0120 | -0.0010 | -7.7% | $0.0130 | $0.0130 | $0.0100 | 223,700 | |
| $0.0130 | +0.0030 | +30.0% | $0.0100 | $0.0130 | $0.0100 | 272,800 | |
| $0.0100 | 0.0000 | 0.0% | $0.0100 | $0.0110 | $0.0100 | 401,200 | |
| $0.0100 | -0.0010 | -9.1% | $0.0120 | $0.0120 | $0.0100 | 474,400 | |
| $0.0110 | -0.0010 | -8.3% | $0.0120 | $0.0130 | $0.0100 | 483,000 | |
| $0.0120 | +0.0010 | +9.1% | $0.0100 | $0.0130 | $0.0100 | 1,059,900 | |
| $0.0110 | 0.0000 | 0.0% | $0.0080 | $0.0120 | $0.0080 | 1,060,300 | |
| $0.0110 | -0.0050 | -31.3% | $0.0130 | $0.0160 | $0.0100 | 1,712,300 | |
| $0.0160 | +0.0040 | +33.3% | $0.0120 | $0.0160 | $0.0120 | 1,807,100 | |
| $0.0120 | -0.0010 | -7.7% | $0.0130 | $0.0140 | $0.0120 | 699,700 | |
| $0.0130 | +0.0020 | +18.2% | $0.0110 | $0.0130 | $0.0100 | 2,324,600 | |
| $0.0110 | +0.0010 | +10.0% | $0.0100 | $0.0110 | $0.0090 | 28,500 | |
| $0.0100 | +0.0010 | +11.1% | $0.0080 | $0.0100 | $0.0080 | 262,200 | |
| $0.0090 | +0.0010 | +12.5% | $0.0100 | $0.0100 | $0.0090 | 198,400 | |
| $0.0080 | -0.0020 | -20.0% | $0.0090 | $0.0110 | $0.0080 | 1,439,300 | |
| $0.0100 | 0.0000 | 0.0% | $0.0100 | $0.0120 | $0.0100 | 475,900 | |
| $0.0100 | -0.0010 | -9.1% | $0.0120 | $0.0120 | $0.0100 | 83,900 | |
| $0.0110 | 0.0000 | 0.0% | $0.0100 | $0.0120 | $0.0100 | 145,800 |
Splits
2 splits since 2025 · OTC:CERO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation | |
| 1-for-100 | Consolidation |
- Ticker
- OTC:CERO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 20, 2026
SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement
Latest deck · Jan 7, 2026
Corporate Update (January 2026)
Corporate update · 15 slides
Latest news
SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement
Nov 20, 2026
Closed $0.0037 (-7.5%) on Nov 20, 2026
CERo Therapeutics Doses 7th Patient in Phase 1 CER-1236 Trial
Nov 3, 2026
Closed $0.0050 (+25.0%) on Nov 3, 2026
CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
Oct 26, 2026
Closed $0.0050 (-16.7%) on Oct 27, 2026
CERo Therapeutics Holdings, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 6 in the last 12 months · 6 in all · newest Nov 20, 2026 · oldest 2026
- Decks
- 7 decks · latest Jan 7, 2026
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$190,890 USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.47
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| Mushrooms, Inc. · OTC:MSRM | US$539,339 | US$564,177 | n/a | n/a | n/a | n/a | n/a | n/a | 1.24 |
| Jaguar Health, Inc. · NASDAQ:JAGX | US$527,406 | −US$1.48M | n/a | −0.1× | n/a | 0.0× | −181.8% | 0.2× | 3.75 |
| Altamira Therapeutics Ltd. · OTC:CYTOF | US$404,655 | US$400,900 | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.64 |
| NKGen Biotech Inc. · OTC:NKGN | US$391,807 | US$38.58M | n/a | n/a | n/a | n/a | n/a | n/a | 0.88 |
| Vaxil Bio Ltd. · TSXV:VXL | US$319,522 | −US$4,071 | 1.2× | n/a | n/a | 0.4× | n/a | 0.0× | -0.16 |
| Chimeric Therapeutics Limited · ASX:CHM | US$292,816 | −US$220,193 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| GlucoTrack, Inc. · NASDAQ:GCTK | US$217,049 | −US$887,951 | n/a | n/a | n/a | n/a | n/a | n/a | 1.73 |
| Regen BioPharma, Inc. · OTC:RGBP | US$167,528 | US$167,289 | n/a | 0.7× | n/a | n/a | −501.4% | n/a | 1.20 |
| CNBX Pharmaceuticals Inc. · OTC:CNBX | US$160,577 | US$151,090 | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| Median of the others | US$306,169 | US$73,510 | 1.2× | −0.1× | 0.1× | −262.8% | 0.0× | 1.20 |
Forecasts
1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 30.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.50 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Chris Ehrlich | Chief Executive Officer & Chair |
| Andrew Albert Al Kucharchuk | Chief Financial Officer & Director |
| Kristen Pierce | Chief Development Officer & Director |
Board
| Director | Role |
|---|---|
| Chris Ehrlich | Chief Executive Officer & Chair |
| Andrew Albert Al Kucharchuk | Chief Financial Officer & Director |
| Brandon Cieniewicz | Director |
| Brian Atwood | Director |
| Eric Francois | Director |
| Kathleen LaPorte | Director |
| Kristen Pierce | Chief Development Officer & Director |
| Lindsey Rolfe | Director |
| Michael Byrnes | Director |
| Shami Patel | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2025 | Nov 19, 2025 · After close | +16.7% |
| Q2 2025 | Aug 22, 2025 · After close | −5.3% |
| Q1 2025 | May 15, 2025 · After close | +0.2% |
| Quarter to Dec 31, 2024 | Feb 26, 2025 | +3.2% |
| Q4 2022 | Mar 24, 2023 | 0.0% |
| Q3 2022 | Nov 10, 2022 | +0.1% |
| Q2 2022 | Aug 11, 2022 | 0.0% |
| Q1 2022 | May 13, 2022 | +0.0% |
| Quarter to Dec 31, 2021 | Mar 24, 2022 | +0.1% |
| Q3 2021 | Nov 19, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (January 2026) | Corporate update | 15 slides | Jan 7, 2026 |
| Investor Presentation (September 2025) | Investor deck | 22 slides | Sep 22, 2025 |
| Investor Presentation (April 2025) | Investor deck | 23 slides | Apr 25, 2025 |
| Phoenix Biotech Acquisition — SPAC Merger (August 2023) | SPAC merger | 46 slides | Aug 14, 2023 |
| Phoenix Biotech Acquisition — SPAC Merger (June 2023) | SPAC merger | 45 slides | Jun 5, 2023 |
| SPAC Merger (June 2023) | SPAC merger | 45 slides | Jun 5, 2023 |
| Phoenix Biotech Acquisition — SPAC Merger (October 2022) | SPAC merger | 32 slides | Oct 31, 2022 |
IPO
Went public as PHOENIX BIOTECH ACQUISITION CORP., a blank check company (SPAC). Priced at US$10.00 a unit on Oct 5, 2021.
- Price
- US$10.00 a unit
- Units offered
- 15,500,000 units
- Offering size
- US$155 million
- Underwriters' option
- Up to 2,325,000 more units
- Underwriter
- Cantor
- Units delivered
- On or about Oct 8, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 8, 2021 |
| Filed publicly | Sep 13, 2021 |
| Amended twice | Newest Sep 28, 2021 |
| Shares registered with an exchange | Oct 5, 2021 |
| Declared effective by the SEC | Oct 5, 2021 |
| Final prospectus, with the price | Oct 8, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 8, 2021 |
| EFFECT · Notice that a registration is effective | Oct 5, 2021 |
| CERT · Exchange's certificate of listing | Oct 5, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 5, 2021 |
| CORRESP · Letter to the SEC | Oct 1, 2021 |
| CORRESP · Letter to the SEC | Oct 1, 2021 |
| S-1/A · Registration statement, amended | Sep 28, 2021 |
| S-1/A · Registration statement, amended | Sep 21, 2021 |
| S-1 · Registration statement | Sep 13, 2021 |
| UPLOAD · Letter from the SEC | Jul 27, 2021 |
All 11 filings
| Filing | Filed |
|---|---|
| DRS · Draft registration statement | Jul 8, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 8, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2023 | FY2022 |
|---|---|---|---|
| Research and development | 5.29M | ||
| Operating income | -7.68M | -2.91M | |
| Interest expense | -138.3K | ||
| Income before tax | -19.9M | -2.44M | -68.6K |
| Income tax | 94.8K | 599.2K | |
| Net income | -19.9M | -7.29M | -667.7K |
| Earnings per share, basic | -0.24 | -1,248.64 | -0.05 |
| Earnings per share, diluted | -1,248.64 |
Balance sheet
| Line | FY2025 | FY2023 | FY2022 |
|---|---|---|---|
| Cash and equivalents | 1.70M | 96.9K | 475.9K |
| Current assets | 2.73M | 1.97M | 42.4M |
| Property, plant and equipment | 246.1K | 966.7K | |
| Total assets | 3.64M | 5.13M | 42.4M |
| Accounts payable | 7.58M | 1.67M | |
| Current liabilities | 9.09M | 3.51M | 30.7M |
| Total liabilities | 9.09M | 5.08M | 39.9M |
| Shareholders' equity | -5.45M | -42.1M | -11.0M |
| Shares outstanding | 83.3M | 5.84K | 14.7M |
Cash flow
| Line | FY2025 | FY2023 | FY2022 |
|---|---|---|---|
| Cash from operations | -16.1M | -1.52M | -1.09M |
| Cash from investing | -7.94M | 180.8M | |
| Cash from financing | -32.6M | -138.7M | |
| Dividends paid | -127.1K | ||
| Share buybacks | -33.5M | -139.4M | |
| Change in cash | -42.0M | 41.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 7, 2026 | Material contract | SEC |
| 8-K · Current report | Aug 31, 2026 | Material contract | SEC |
| 424B3 · Prospectus | Aug 14, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jul 17, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 17, 2026 | Material contract | SEC |
| 25-NSE | Jul 13, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jun 26, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jun 26, 2026 | Material contract | SEC |
| 424B3 · Prospectus | May 29, 2026 | Offer document | SEC |
| 8-K · Current report | May 29, 2026 | Material contract | SEC |
| 424B3 · Prospectus | May 15, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 424B3 · Prospectus | May 1, 2026 | Offer document | SEC |
| 8-K · Current report | May 1, 2026 | Material contract | SEC |
| 424B3 · Prospectus | May 1, 2026 | Offer document | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2026 | Annual report | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 21, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Apr 15, 2026 | Offer document | SEC |
| 10-K · Annual report | Apr 15, 2026 | Annual report | SEC |
| 424B3 · Prospectus | Apr 14, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 14, 2026 | Material contract | SEC |
| NT 10-K · Late filing notice | Apr 1, 2026 | Explanation request | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 12, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Mar 10, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 10, 2026 | Material contract | SEC |
| 424B3 · Prospectus | Feb 20, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 13, 2026 | Material contract | SEC |
| 424B3 · Prospectus | Feb 4, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 4, 2026 | Current report | SEC |
| 424B3 · Prospectus | Feb 3, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Jan 8, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 7, 2026 | Current report | SEC |
| 424B3 · Prospectus | Dec 19, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 19, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Dec 12, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 9, 2025 | Other filings | SEC |
| S-1 · Registration statement | Dec 5, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 2, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 2, 2025 | Offer document | SEC |
| DEFA14A · Additional proxy material | Dec 2, 2025 | Meeting notice | SEC |
| 8-K · Current report | Dec 2, 2025 | Material contract | SEC |
| DEF 14A · Proxy statement | Nov 28, 2025 | Meeting notice | SEC |
| 424B3 · Prospectus | Nov 20, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 20, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 19, 2025 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Nov 17, 2025 | Explanation request | SEC |
| PRE 14A · Preliminary proxy statement | Nov 14, 2025 | Meeting notice | SEC |
| 424B3 · Prospectus | Oct 30, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 30, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 29, 2025 | Current report | SEC |
| 424B3 · Prospectus | Oct 23, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 23, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 16, 2025 | Material contract | SEC |
| 8-K · Current report | Oct 14, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 22, 2025 | Current report | SEC |
| 424B3 · Prospectus | Sep 5, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Sep 5, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 5, 2025 | Current report | SEC |
| 424B3 · Prospectus | Sep 4, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Sep 4, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 4, 2025 | Current report | SEC |
| 424B3 · Prospectus | Aug 22, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 22, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 22, 2025 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Aug 18, 2025 | Other filings | SEC |
| NT 10-Q · Late filing notice | Aug 15, 2025 | Explanation request | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Aug 14, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 14, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 8, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 30, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jul 28, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 28, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jul 25, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jul 25, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jul 21, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 18, 2025 | Financing | SEC |
| 424B3 · Prospectus | Jul 14, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 14, 2025 | Material contract | SEC |
| 8-K · Current report | Jul 8, 2025 | Current report | SEC |
| 424B3 · Prospectus | Jul 2, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 30, 2025 | Material contract | SEC |
| 424B3 · Prospectus | Jun 25, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 17, 2025 | Current report | SEC |
| 424B3 · Prospectus | Jun 16, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 13, 2025 | Current report | SEC |
| 8-K · Current report | Jun 11, 2025 | Current report | SEC |
| 424B3 · Prospectus | Jun 6, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 6, 2025 | Financing | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 2, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | May 30, 2025 | Other filings | SEC |
| 8-K · Current report | May 29, 2025 | Management or board change | SEC |
| POS AM · Amendment to an effective registration | May 23, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 8, 2025 | Current report | SEC |
| 3/A · Initial statement of ownership, amended | May 8, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | May 7, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | May 6, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | May 6, 2025 | Meeting notice | SEC |
| D | May 6, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 2, 2025 | Other filings | SEC |
| PRER14A | May 2, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 1, 2025 | Other filings | SEC |
| 10-K/A · Annual report, amended | Apr 28, 2025 | Annual report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 25, 2025 | Current report | SEC |
| 8-K · Current report | Apr 22, 2025 | Material contract | SEC |
| 10-K · Annual report | Apr 15, 2025 | Annual report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| NT 10-K · Late filing notice | Apr 1, 2025 | Explanation request | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Feb 13, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 13, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 13, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 13, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 12, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Feb 7, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 6, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Feb 6, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 5, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 5, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 3, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 31, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 28, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 27, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 23, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jan 23, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 23, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 23, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 23, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 21, 2025 | Current report | SEC |
| S-1/A · Registration statement, amended | Jan 21, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 14, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 14, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 14, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 14, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 10, 2025 | Financing | SEC |
| 424B3 · Prospectus | Jan 7, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 7, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 7, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 7, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 7, 2025 | Current report | SEC |
| 8-K · Current report | Jan 6, 2025 | Current report | SEC |
| 424B3 · Prospectus | Jan 3, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 3, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 3, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 31, 2024 | Financing | SEC |
| UPLOAD · Letter from the SEC | Dec 26, 2024 | Other filings | SEC |
| S-1 · Registration statement | Dec 23, 2024 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 17, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Dec 13, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Dec 9, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 6, 2024 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Dec 6, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Dec 6, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Dec 5, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Dec 5, 2024 | Offer document | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
This page holds 200 of 446 filings. Open Filings
Cap table
Built by 6ix from CERo Therapeutics Holdings, Inc.’s releases
- Common shares
- 71,630,992
- Fully diluted
- 71,630,992
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 71,630,992 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 71,630,992 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Andrew Kucharchuk Other companies: RRE Ventures Acquisition Corp. (Chief Financial Officer · Since at least Apr 29, 2026); Range Capital Acquisition Corp II (Chief Financial Officer · Since at least Oct 2, 2025); Windtree Therapeutics, Inc. (Director · Since at least Aug 3, 2025); Chain Bridge I (Chief Financial Officer · Apr 1, 2024 – Apr 1, 2024 · Past); Adhera Therapeutics Inc. (Chief Executive Officer, Director · Jul 7, 2020 – Jul 7, 2020 · Past); OncBioMune Pharmaceuticals Inc (Director · May 9, 2018 – Jun 5, 2020 · Past) | Chief Financial Officer & Director · Since at least Oct 1, 2024 |
| Caroline M Loewy Other companies: eFFECTOR Therapeutics Inc (Director · Sep 9, 2023 – Jun 13, 2024 · Past); Zogenix Inc (Director · Sep 21, 2020 – Mar 7, 2022 · Past); Aptose Biosciences Inc (Director · Dec 21, 2018 – Jan 18, 2022 · Past); PhaseBio Pharmaceuticals Inc (Director · Oct 17, 2018 – May 19, 2023 · Past) | Director · Oct 5, 2021 – Feb 14, 2024 · Past |
| Christopher B Ehrlich Other companies: Launch One Acquisition Corp. (Chief Executive Officer, Director · Jul 11, 2024 – Jul 11, 2024 · Past); eFFECTOR Therapeutics Inc (Director · Aug 25, 2021 – Jun 13, 2024 · Past); Paratek Pharmaceuticals Inc (Director · Jan 30, 2009 – Apr 10, 2013 · Past); Biomimetic Therapeutics Inc (Director · May 10, 2006 – Mar 1, 2013 · Past) | Chairman and CEO, Director · Since at least Oct 5, 2021 |
| Barbara Kosacz Other companies: XOMA Royalty Corporation (Director · Since at least May 21, 2025); LeonaBio, Inc. (Board Member · Since at least Mar 4, 2021); Kronos Bio Inc (COO & General Counsel · Oct 8, 2020 – Jan 4, 2024 · Past) | Director · Oct 5, 2021 – Feb 14, 2024 · Past |
| Douglas Carl Fisher Other companies: Sera Prognostics, Inc. (Chief Business Officer · Jul 14, 2021 – Jan 10, 2022 · Past); Precipio, Inc. (Director · Sep 26, 2017 – Oct 27, 2023 · Past); Vyome Holdings, Inc. (Director · Oct 5, 2016 – Sep 16, 2020 · Past) | President · Oct 5, 2021 – Feb 14, 2024 · Past |
| Eric Francois Other companies: 60 Degrees Pharmaceuticals, Inc. (Director · Since at least May 13, 2026); CervoMed Inc. (Director · Jun 25, 2021 – Jul 1, 2021 · Past); Scynexis, Inc. (Chief Financial Officer · Nov 1, 2015 – Jan 29, 2021 · Past) | Director · Since at least Feb 13, 2026 |
| Lindsey Rolfe Other companies: Atreca Inc (Director · Aug 22, 2019 – Jun 13, 2023 · Past); Clovis Oncology Inc (See Remarks · Aug 3, 2015 – Nov 1, 2022 · Past) | Director · Since at least Feb 14, 2024 |
| Michael Byrnes Other companies: eFFECTOR Therapeutics Inc (Chief Financial Officer · Aug 24, 2021 – May 15, 2024 · Past); Ocera Therapeutics Inc (CFO and Treasurer · Sep 17, 2014 – Dec 11, 2017 · Past) | Director · Since at least Feb 14, 2024 |
| Charles Carter Other companies: Ovid Therapeutics Inc. (Chief Financial Officer · Since at least Jul 6, 2026) | Chief Financial Officer · Feb 14, 2024 – Jun 28, 2024 · Past |
| Chris Ehrlich Other companies: Launch One Acquisition Corp. (Chief Executive Officer · Since at least Nov 13, 2024) | Chief Executive Officer & Chair · Since at least Nov 3, 2026 |
All 17 people
| Person | Seat |
|---|---|
| Brandon Cieniewicz | Director · Since at least Nov 5, 2026 |
| Brian Atwood | Director · Since at least Oct 7, 2026 |
| Daniel Corey | Chief Technical Officer, Director · Feb 14, 2024 – Mar 25, 2024 · Past |
| Kathleen LaPorte | Director · Since at least Nov 5, 2026 |
| Kristen Pierce | Chief Development Officer & Director · Since at least Oct 1, 2024 |
| Robyn Rapaport | Director · Feb 14, 2024 – Mar 25, 2024 · Past |
| Shami Patel | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about CERo Therapeutics Holdings, Inc.